At a glance
- Dasiglucagon was approved by the FDA (Zegalogue, March 22, 2021), but the products are no longer marketed.
- PubMed lists 48 publications mentioning it, including 13 randomized controlled trials and 1 animal-only study.
- ClinicalTrials.gov lists 21 registered studies testing it (0 active).
- FDA's adverse event system (FAERS) holds 53 reports mentioning it; 34 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA214231 | ZEGALOGUE, ZEGALOGUE (AUTOINJECTOR) | Approved, discontinued | March 22, 2021 | ZEALAND PHARMA |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Charge density effect of micelles on liquid-liquid phase separation.
- Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine-Phenylboronic Acid Pendant Modification.
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
- Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event.
- Response to Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
- Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
- Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial.
- Dasiglucagon: a New Hope for Managing Post-prandial Hypoglycemia After Gastric Bypass Surgery?
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.
- Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 21
- Active
- 0
- With posted results
- 9
Conditions studied
Show 11 more studies
All 21 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 53
- Serious
- 34
- With death outcome
- 15
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.